Synergy experiments revealed that pharmacologic IDH1 inhibition rendered TMZ substantially more potent (up to 18-fold at some dosing levels) in melanoma cell lines, A375 and SK-MEL-28 (Fig. 5E and F, Supplementary Fig. S5G and H). Here, IDH1 is linked to melanoma.